CN EN
WEBINAR
This webinar was presented in November 2023. Please enjoy the recording and contact us if you have any questions.

In the dynamic landscape of pharmaceutical development, a multitude of new chemical entities (NCEs) are discovered daily. This constant influx presents formulators with the ongoing challenge of addressing issues related to solubility and permeability, as well as the need for modified release delivery, often with only milligrams of active pharmaceutical ingredient (API) at their disposal.

Learn how to leverage predictive tools to select formulations with the highest likelihood of success. You’ll discover key methods and solutions for expediting the screening process and facilitating seamless scale-up to clinical trial material (CTM) manufacturing.

Watch On-Demand


Learn about our Speaker
doctor-f-a-png.png
Dr. Firouz Asgarzadeh
Senior Vice President of Pharmaceutics, Formulation, Analytical and Process Development
28+ years in CRDMO R&D, specializing in bioavailability enhancement, amorphous solid dispersion and modified release formulation and process development. Formerly Formulation Director at Evonik and Principal Scientist at Merck, and Senior Scientist at Catalent Pharma, AAPS (co)chair (EFG, CROFG and QbD FG), and Ph.D. graduate in Polymeric Materials.
NASH Webinar Coming Soon
Register Today! This online event "Unleashing Innovation: A New Obesogenic NASH Model with High Clinically Translational Power" translates NASH/NAFLD research to clinic with better representative data, faster.
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all